| 000 | 01677 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250517090149.0 | ||
| 264 | 0 | _c20170626 | |
| 008 | 201706s 0 0 eng d | ||
| 022 | _a1941-837X | ||
| 024 | 7 |
_a10.3111/13696998.2016.1173042 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPilon, Dominic | |
| 245 | 0 | 0 |
_aCost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer. _h[electronic resource] |
| 260 |
_bJournal of medical economics _cAug 2016 |
||
| 300 |
_a777-84 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAbiraterone Acetate _xeconomics |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xeconomics |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 | _aCosts and Cost Analysis |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Metastasis |
| 650 | 0 | 4 | _aNitriles |
| 650 | 0 | 4 |
_aPhenylthiohydantoin _xanalogs & derivatives |
| 650 | 0 | 4 |
_aPrednisone _xeconomics |
| 650 | 0 | 4 | _aProstate-Specific Antigen |
| 650 | 0 | 4 |
_aProstatic Neoplasms, Castration-Resistant _xdrug therapy |
| 700 | 1 | _aQueener, Marykay | |
| 700 | 1 | _aLefebvre, Patrick | |
| 700 | 1 | _aEllis, Lorie A | |
| 773 | 0 |
_tJournal of medical economics _gvol. 19 _gno. 8 _gp. 777-84 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3111/13696998.2016.1173042 _zAvailable from publisher's website |
| 999 |
_c25879865 _d25879865 |
||